middle.news
Mesoblast Hits 300-Patient Target in Phase 3 Back Pain Trial
10:00am on Tuesday 14th of July, 2026 AEST
•
Healthcare
Read Story
Mesoblast Hits 300-Patient Target in Phase 3 Back Pain Trial
10:00am on Tuesday 14th of July, 2026 AEST
Key Points
Phase 3 trial reaches full enrollment of 300 patients
Rexlemestrocel-L targets chronic low back pain with single injection
FDA RMAT designation enables priority review pathway
Trial includes opioid cessation and quality of life endpoints
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE